Secukinumab 2-weekly vs. 4-weekly Dosing in Plaque Psoriasis Secukinumab 2-weekly vs. 4-weekly Dosing in Plaque Psoriasis
This study showed a potential benefit of secukinumab dosing every 2 weeks in psoriasis patients who did not respond optimally to secukinumab treatment every 4 weeks.The British Journal of Dermatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 28, 2021 Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news

Detecting skin disorders based on tissue stiffness with a soft sensing device
(City University of Hong Kong) A research team co-led by a scientist from City University of Hong Kong (CityU) has designed a simple electromechanical device that can be used for deep tissue pathology diagnosis, such as psoriasis, in an automated and non-invasive fashion. The findings will lay a foundation for future applications in the clinical evaluation of skin cancers and other dermatology diseases. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 28, 2021 Category: International Medicine & Public Health Source Type: news

Risk for Autoimmunity Up With Concomitant Vitiligo, Psoriasis
WEDNESDAY, May 26, 2021 -- Individuals with co-occurrence of vitiligo and psoriasis have an increased risk for autoimmunity and family history of psoriasis, according to a research letter published online May 20 in the Journal of the European... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 26, 2021 Category: Pharmaceuticals Source Type: news

Arthritis drug may limit COVID-19 vaccine effectiveness, study finds
COVID-19 vaccines may not be as effective in people who take a drug for rheumatoid arthritis and psoriasis, according to a study published Tuesday by the journal Annals of Rheumatic Diseases. (Source: Health News - UPI.com)
Source: Health News - UPI.com - May 25, 2021 Category: Consumer Health News Source Type: news

Janssen Presents Results of First Head-to-Head Study of Biologic Therapies in Patients with Moderate to Severe Crohn ’s Disease
SPRING HOUSE, PENNSYLVANIA, May 23, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced efficacy and safety data for STELARA® (ustekinumab) in Crohn’s disease (CD) and ulcerative colitis (UC),1-4including data from the SEAVUE study, the first head-to-head study of biologic therapies in patients with CD, presented in a Clinical Science Late-Breaking Abstract Plenary session.1 SEAVUE data showed treatment with STELARA demonstrated high rates of clinical remission, corticosteroid-free remission, clinical response and endoscopic response through one year in biologic-naïve patients with mo...
Source: Johnson and Johnson - May 24, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

More Body Surface Area Clearance With Psoriasis Tied to Better Quality of Life
Findings consistent at both six and 12 months of treatment with systemic therapy (Source: The Doctors Lounge - Psychiatry)
Source: The Doctors Lounge - Psychiatry - May 22, 2021 Category: Psychiatry Tags: Dermatology, Family Medicine, Internal Medicine, Pharmacy, Psychiatry, Journal, Source Type: news

Using'Court Awareness' to Practice More Efficiently Using'Court Awareness' to Practice More Efficiently
' The clinic has been busy lately. Vaccinated patients are returning after a year with their skin cancers that have flourished and psoriasis covering them like kudzu, ' said Dr Jeffrey Benabio, on managing his patients.Medscape Dermatology (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - May 21, 2021 Category: Dermatology Tags: Dermatology Commentary Source Type: news

More Body Surface Area Clearance With Psoriasis Tied to Better Quality of Life
FRIDAY, May 21, 2021 -- Greater skin clearance among psoriasis patients is associated with greater improvements in quality of life, according to a letter to the editor published in the June issue of the Journal of the American Academy of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 21, 2021 Category: Pharmaceuticals Source Type: news

Certolizumab Pegol in Psoriasis: Considerations for Pregnancy Certolizumab Pegol in Psoriasis: Considerations for Pregnancy
Is the anti-tumor necrosis factor-alpha agent certolizumab pegol safe to use in pregnant patients? Review the latest data in this article.Skin Therapy Letter (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 18, 2021 Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news

Adverse childhood experience in patients with psoriasis - Akamine AA, Rusch GS, Nisihara R, Skare TL.
INTRODUCTION: Adverse childhood experiences (ACEs) have been linked to the occurrence of autoimmune diseases in adults, including psoriasis. AIM: To study the prevalence of ACEs in psoriasis patients comparing it with general population. ME... (Source: SafetyLit)
Source: SafetyLit - May 17, 2021 Category: International Medicine & Public Health Tags: Age: Adolescents Source Type: news

Scientists show immune cells change behavior unexpectedly to instigate psoriasis lesions
(University of Chicago) Study shows that   when exposed to a trigger, certain kinds of immune cells change their behavior in unexpected ways to produce the protein signals that cause lesions. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 13, 2021 Category: International Medicine & Public Health Source Type: news

The Differences Between Eczema and Psoriasis
What Are the Differences Between Eczema and Psoriasis? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - May 11, 2021 Category: General Medicine Source Type: news

How Do You Get Rid of Psoriasis on Your Scalp
? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - May 11, 2021 Category: General Medicine Source Type: news

5:2 diet helps reduce skin symptoms in Psoriasis patients
(Say Communications) New research investigating for the first time the effects of modified intermittent fasting (MIF) on the skin of people with psoriasis has yielded promising results. Preliminary study findings presented today at the EADV Spring Symposium, show a significant reduction in scaling and thickness in patients with mild psoriasis after following a MIF 5:2 diet (eating normally for 5 days and restricting calorie intake on 2 non-consecutive days). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 6, 2021 Category: International Medicine & Public Health Source Type: news

Jab ends scaly skin misery for 60% of psoriasis patients
Libby Quayle, right, from Manchester, pictured with her friend Paiton Barker, has enrolled in a clinical trial to test the efficacy of the new psoriasis treatment bimekizumab. (Source: the Mail online | Health)
Source: the Mail online | Health - May 1, 2021 Category: Consumer Health News Source Type: news